PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers

Background Combining PARP inhibitors (PARPis) with immune checkpoint inhibitors may improve clinical outcomes in selected cancers. We evaluated rucaparib and atezolizumab in advanced gynaecological or triple-negative breast cancer (TNBC). Methods After identifying the recommended dose, patients with...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2024-07, Vol.131 (5), p.820-831
Hauptverfasser:	Kristeleit, Rebecca, Leary, Alexandra, Oaknin, Ana, Redondo, Andres, George, Angela, Chui, Stephen, Seiller, Aicha, Liste-Hermoso, Mario, Willis, Jenna, Shemesh, Colby S., Xiao, Jim, Lin, Kevin K., Molinero, Luciana, Guan, Yinghui, Ray-Coquard, Isabelle, Mileshkin, Linda
Format:	Artikel
Sprache:	eng
Schlagworte:	692/4028/67/1059/2325 692/4028/67/1059/2326 692/4028/67/1059/602 692/4028/67/1517/1709 692/53/2423 Apoptosis Biomedical and Life Sciences Biomedicine Biopsy Breast cancer Cancer Research CD8 antigen Cell activation DNA damage DNA repair Drug Resistance Epidemiology Gynecology Heterozygosity Homologous recombination Immune checkpoint inhibitors Immunotherapy Lymphocytes T Molecular Medicine Monoclonal antibodies Oncology Ovarian cancer Patients PD-L1 protein Poly(ADP-ribose) polymerase Targeted cancer therapy Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!